Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

16 Sep 2005 13:06

ReNeuron Group plc16 September 2005 NOTIFICATION OF TRANSACTIONS OF DIRECTORS/PERSONS DISCHARGINGMANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transactionrelating to the shares or debentures of the issuer should complete boxes 1 to16, 23 and 24. (2) An issuer making a notification in respect of a derivative relatingto the shares of the issuer should complete boxes 1 to 4, 6, 8,13, 14, 16, 23and 24. (3) An issuer making a notification in respect of options granted to adirector/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financialinstrument relating to the shares of the issuer (other than a debenture) shouldcomplete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or RENEURON GROUP PLC (ii) DR3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) (ii) 3. Name of person discharging managerial 4. State whether notification relates to a person responsibilities/director connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person JOHN SINDEN MICHAEL HUNT 5. Indicate whether the notification is in 6. Description of shares (including class), respect of a holding of the person referred debentures or derivatives or financial to in 3 or 4 above or in respect of a instruments relating to shares non-beneficial interest3 7. Name of registered shareholders(s) and, if 8. State the nature of the transaction more than one, the number of shares held by each of them 9. Number of shares, debentures or financial 10. Percentage of issued class acquired (treasury instruments relating to shares acquired shares of that class should not be taken into account when calculating percentage) 11. Number of shares, debentures or financial 12. Percentage of issued class disposed (treasury instruments relating to shares disposed shares of that class should not be taken into account when calculating percentage) 13. Price per share or value of transaction 14. Date and place of transaction 15. Total holding following notification and 16. Date issuer informed of transaction total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17. Date of grant 18. Period during which or date on which it can be exercised ANY TIME DURING THE PERIOD ENDING 23 JULY 2014 6 SEPTEMBER 2005 19. Total amount paid (if any) for grant of the 20. Description of shares or debentures involved option (class and number) JOHN SINDEN 650,000 ORDINARY SHARES NIL MICHAEL HUNT 900,000 ORDINARY SHARES 21. Exercise price (if fixed at time of grant) 22. Total number of shares or debentures over or indication that price is to be fixed at the time which options held following notification of exercise £0.10 PER SHARE JOHN SINDEN 1,955,260 OPTIONS AND WARRANTS MICHAEL HUNT 1,929,500 OPTIONS AND WARRANTS 23. Any additional information 24. Name of contact and telephone number for queries TIM MICKLEY, COLLINS STEWART 020 7523 8000 REPLACEMENT OPTIONS GRANTED UNDER THE COMPANY'S NEW SHARE OPTION SCHEME MICHAEL HUNT RENEURON 01483 302 560 Name and signature of duly authorised officer of issuer responsible for making notification MICHAEL HUNT CHIEF EXECUTIVE OFFICER-______________________________________ Date of notification 16/9/05 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
18th Nov 20217:00 amRNSNotice of Results
1st Nov 20217:00 amRNSTotal Voting Rights
26th Oct 20213:09 pmRNSDirector exit arrangements
26th Oct 20217:00 amRNSCollaboration agreement with UCL
21st Oct 20217:00 amRNSDirector Share Purchase
20th Oct 20217:00 amRNSDirector/PDMR Interest in Share Options
18th Oct 20217:00 amRNSFurther changes in the Board of Directors
18th Oct 20217:00 amRNSFirst subject treated at Oxford Eye Hospital
12th Oct 20212:05 pmRNSSecond Price Monitoring Extn
12th Oct 20212:01 pmRNSPrice Monitoring Extension
11th Oct 20214:40 pmRNSSecond Price Monitoring Extn
11th Oct 20214:35 pmRNSPrice Monitoring Extension
11th Oct 20212:06 pmRNSSecond Price Monitoring Extn
11th Oct 20212:00 pmRNSPrice Monitoring Extension
11th Oct 202111:05 amRNSSecond Price Monitoring Extn
11th Oct 202111:00 amRNSPrice Monitoring Extension
11th Oct 20219:05 amRNSSecond Price Monitoring Extn
11th Oct 20219:00 amRNSPrice Monitoring Extension
11th Oct 20217:00 amRNSPositive data generated in exosome collaboration
1st Oct 20217:00 amRNSRegulatory approval for continuation of RP trial
16th Sep 20214:26 pmRNSResult of AGM
2nd Sep 202112:00 pmRNSBlock Listing Review, Application and TVR
16th Aug 20212:20 pmRNSPosting of AR and Accounts and Notice of AGM
6th Aug 20217:00 amRNSDirectorate Change
14th Jul 20217:00 amRNSBoard Change
8th Jul 20217:00 amRNSPreliminary Results for the year ended 31 March 21
2nd Jul 20211:00 pmRNSNotice of Results
2nd Jul 20217:00 amRNSNotice of Results
1st Jul 20217:00 amRNSDirectorate Change
1st Jul 20217:00 amRNSTotal Voting Rights
18th Jun 202110:48 amRNSHolding(s) in Company
9th Jun 20214:36 pmRNSPrice Monitoring Extension
9th Jun 20212:05 pmRNSSecond Price Monitoring Extn
9th Jun 20212:00 pmRNSPrice Monitoring Extension
9th Jun 202111:55 amRNSUpdate for hRPC therapy candidate study
7th Jun 20215:25 pmRNSHolding(s) in Company
20th May 20217:00 amRNSAppointment of Chief Scientific Officer
4th May 20217:00 amRNSTotal Voting Rights
29th Apr 20217:00 amRNSInitiation of research by Allenby Capital
6th Apr 20217:00 amRNSVirtual conference attendance and presentations
30th Mar 20217:00 amRNSHolding(s) in Company
19th Mar 20217:00 amRNSExosome platform update
16th Mar 20214:05 pmRNSHolding(s) in Company
16th Mar 202110:57 amRNSHolding(s) in Company
16th Mar 20217:00 amRNSHolding(s) in Company
12th Mar 20217:00 amRNSDirectorate Change
1st Mar 20217:00 amRNSBlock Listing Review and Total Voting Rights
25th Feb 20217:01 amRNSInvestor presentations
25th Feb 20217:00 amRNSAppointment of Joint Broker
11th Feb 20217:00 amRNSDirector/PDMR Interest in Shares and Share Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.